Nearly every health plan sold in New York requires prior authorization before it will pay for infliximab, the tumor necrosis factor blocker sold as Remicade and as the biosimilars Inflectra, Renflexis and Avsola, alongside unbranded infliximab. Prime Infusions administers all five products across 13 infusion centers in New York and files these requests with prescribing physicians as routine work.
What surprises patients most is that an infliximab denial often has nothing to do with whether infliximab is the right drug. It has to do with which infliximab product was requested. This article covers that distinction, the documentation a request needs, when a biosimilar switch triggers a new authorization, where a plan will approve the infusion, and what New York law provides after a denial. For the therapy itself, see our Remicade treatment page.
What Is Prior Authorization for Infliximab, and Why Does Nearly Every Plan Require It?
Prior authorization is a written approval a health plan issues before it will pay for a particular drug for a particular patient. Infliximab is administered by a clinician rather than self-administered, so it is billed under the medical benefit, which for Medicare beneficiaries means Part B rather than Part D. Two large national policies show what the review looks like: the UnitedHealthcare Commercial Medical Benefit Drug Policy for Infliximab (Avsola, Inflectra, Remicade & Renflexis), Policy 2026D0004AR, effective February 1, 2026, and the Cigna Infliximab Intravenous Products Preferred Specialty Management Policy, Coverage Policy PSM005, effective 08/15/2026.
The dose is part of what the plan approves. According to the FDA-approved REMICADE prescribing information, revised 2/2025, infliximab is dosed by body weight on an induction schedule at weeks 0, 2 and 6: 5 mg/kg for most indications, and 3 mg/kg for rheumatoid arthritis, where the labeled indication is in combination with methotrexate.
Why Would a Plan Deny Remicade When It Covers Infliximab?
Because large commercial plans now designate particular infliximab products as preferred, and a request for a non-preferred product is measured against extra criteria. UnitedHealthcare Policy 2026D0004AR names Inflectra (infliximab-dyyb) and Avsola (infliximab-axxq) as the preferred products. To obtain Remicade, Renflexis or another non-preferred infliximab under medical necessity plans, that policy requires "Documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response to therapy and residual disease activity," plus a prescriber attestation, or else "Documentation of intolerance, contraindication, or adverse event to Inflectra or Avsola." Cigna PSM005 has the same shape: preferred products are "Avsola, Inflectra," non-preferred are "infliximab (authorized generic), Remicade, Renflexis," and the policy "directs the patient to try at least one Preferred Product prior to the approval of a Non-Preferred Product."
This distinction is worth carrying to your prescriber. A denial that follows a Remicade request may not be a judgment about infliximab at all; it can be a step therapy requirement attached to the product. Notice which way it runs: Remicade, the originator first approved in the United States in 1998, is the non-preferred product on both policies, which is the reverse of what most patients assume. Preferred and non-preferred are the payers' own formulary terms, not a clinical ranking, and the FDA standard a biosimilar meets is that it is highly similar to the reference product with no clinically meaningful differences. The useful question is therefore not why the infusion was denied, but which infliximab product is preferred on your plan right now and whether your chart supports an exception.
| Infliximab product | UnitedHealthcare 2026D0004AR, effective 02/01/2026 | Cigna PSM005, effective 08/15/2026 |
|---|---|---|
| Inflectra (infliximab-dyyb) | Preferred | Preferred |
| Avsola (infliximab-axxq) | Preferred | Preferred |
| Remicade (infliximab) | Non-preferred | Non-preferred |
| Renflexis (infliximab-abda) | Non-preferred | Non-preferred |
| Unbranded infliximab | Handled as another non-preferred infliximab product | Non-preferred, listed as "infliximab (authorized generic)" |
Does Switching to a Biosimilar Require a New Prior Authorization?
Often, yes. An authorization is issued for a named product at a named dose and interval, and frequently for a named site of care, so a change to any of those can require a fresh request rather than a continuation. A product change is a genuine change, because no infliximab product carries an FDA interchangeability designation. The FDA biosimilar product information list and the Purple Book records show Inflectra (BLA 125544, approved April 5, 2016), Renflexis (BLA 761054, April 21, 2017) and Avsola (BLA 761086, December 6, 2019) as 351(k) biosimilars, none designated interchangeable with Remicade. Because New York's biological substitution statute is gated on interchangeability, an infliximab switch happens through a new prescriber order interacting with the plan's policy, not through a pharmacist substituting.
One product name causes recurring confusion here. Unbranded infliximab is Janssen Biotech's own unbranded version of Remicade under the same license; it is not a biosimilar, and Cigna PSM005 lists it as "infliximab (authorized generic)." Product detail sits on the Prime Infusions pages for Inflectra, Avsola, Renflexis and unbranded infliximab. What a payer-driven switch changes on infusion day is covered in the article on an insurance switch from Remicade to a biosimilar.
What Documentation Does an Infliximab Prior Authorization Request Need?
Infliximab requests stall on a missing element more often than on a wrong diagnosis. The packet is consistent across payers and products:
- The diagnosis with its ICD-10 code, plus the clinical findings the plan's policy attaches to it.
- A current weight in kilograms, because infliximab dosing is mg/kg.
- Latent tuberculosis screening status, with the result and the date.
- Prior therapy history: which drugs were tried, for how long, and why each was stopped.
- The physician's order naming product, dose, infusion rate and interval.
The tuberculosis element is required twice over. Every infliximab product carries the FDA boxed warning headed WARNING: SERIOUS INFECTIONS and MALIGNANCY, which directs that "Patients should be tested for latent tuberculosis before REMICADE use and during therapy" and that "Treatment for latent infection should be initiated prior to REMICADE use." It is also a coverage requirement. The Medicare contractor billing article for infliximab and biosimilars, CMS Article A52423, revision effective 04/01/2026, requires documentation of "tuberculosis evaluation and treatment initiated before therapy," the patient's weight, and evidence of inadequate response to a 3-month trial of conventional non-biologic therapy.
Where Will Your Plan Approve Your Infliximab Infusions?
Increasingly at a non-hospital site. The UnitedHealthcare Provider Administered Drugs Site of Care policy, Policy 2026D0121V, effective August 1, 2026, lists Remicade, Inflectra, Renflexis and Avsola within its scope and states that "Alternative Sites of Care, such as non-hospital outpatient infusion, physician office, ambulatory infusion suites, or home infusion services are well accepted places of service for medication infusion therapy." Hospital outpatient infusion is approved on that policy's enumerated criteria only. Site of care is a plan determination made on the individual's coverage and clinical facts, so no infusion provider can say in advance where your plan will approve your infliximab. Prime Infusions operates 13 infusion centers across New York, among them the Manhattan infusion center on the Upper East Side, the Brooklyn infusion center on Foster Avenue and the Queens infusion center in Fresh Meadows. What the setting does to the bill is covered in the article on why the same infusion costs more at a hospital.
What Are Your Rights in New York After an Infliximab Denial?
New York gives the prescriber a statutory route around step therapy, and gives the patient an appeal decided outside the plan. Under New York Insurance Law section 4903 and the parallel Public Health Law provision, a plan must grant a step therapy override where the prescribing physician establishes one of the statutory grounds, among them that the required drug is contraindicated, that it is expected to be ineffective given the patient's clinical history, that it was already tried and discontinued for lack of effectiveness, or that the patient is stable on the drug the prescriber selected. The override determination is due within 72 hours of receipt of the supporting information, and within 24 hours where delay would put the patient's health in serious jeopardy. If a medical necessity denial survives the plan's internal appeal, New York's Article 49 external appeal sends the dispute to an independent reviewer; the application must be filed within 45 days of the final adverse determination, and the program is administered by the New York State Department of Financial Services. The companion article on IVIG prior authorization in New York sets out the same New York machinery in full.
How Does Prime Infusions Handle Your Infliximab Authorization?
Prime Infusions verifies your benefits and submits the prior authorization request together with your prescribing physician, and refiles it when the product or the site of care changes. Coverage is determined by your health plan, and no infusion provider can promise an approval. What Prime Infusions can do is send a complete request the first time, and file the step therapy override or the appeal when the product the prescriber wants is the non-preferred one. Patients and caregivers can start with the Remicade and infliximab request form; referring physicians can use the Prime Infusions referrals page or call 718-443-4000. The therapy itself is described on the Remicade page at Prime Infusions.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. Every infliximab product carries an FDA boxed warning headed "WARNING: SERIOUS INFECTIONS and MALIGNANCY", covering serious infections including tuberculosis and invasive fungal infection, and malignancy including lymphoma and hepatosplenic T-cell lymphoma; review the full prescribing information for the product prescribed to you and discuss your individual risk factors with your treating clinician. Coverage and out-of-pocket cost are determined by your health plan.